CNBX Pharmaceuticals annual stock-based compensation
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
CNBX Pharmaceuticals Stock-Based Compensation Growth & History (CNBX)
CNBX Pharmaceuticals's stock-based compensation was $0 for fiscal 2025.
View full CNBX Pharmaceuticals company overviewCNBX Pharmaceuticals annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-08-31 | $0 | −$139,720 | — |
| 2024 | 2024-08-31 | $139,720 | −$40,760 | −22.58% |
| 2023 | 2023-08-31 | $180,480 | −$548,389 | −75.24% |
| 2022 | 2022-08-31 | $728,869 | $728,869 | — |
| 2021 | 2021-08-31 | $0 | −$72,120 | — |
| 2020 | 2020-08-31 | $72,120 | −$175,187 | −70.84% |
| 2019 | 2019-08-31 | $247,307 | −$1.6M | −86.66% |
| 2018 | 2018-08-31 | $1.9M | $972,995 | +110.47% |
| 2017 | 2017-08-31 | $880,790 | $850,940 | +2850.72% |
| 2016 | 2016-08-31 | $29,850 | — | — |
CNBX Pharmaceuticals quarterly stock-based compensation
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q1 2026 | 2025-11-30 | $0 | $0 | — |
| Q4 2025 | 2025-08-31 | $0 | −$34,975 | — |
| Q3 2025 | 2025-05-31 | $0 | −$34,795 | — |
| Q2 2025 | 2025-02-28 | $0 | −$34,975 | — |
| Q1 2025 | 2024-11-30 | $0 | −$34,975 | — |
| Q4 2024 | 2024-08-31 | $34,975 | $0 | 0.00% |
| Q3 2024 | 2024-05-31 | $34,795 | −$180 | −0.51% |
| Q2 2024 | 2024-02-29 | $34,975 | $2 | +0.01% |
| Q1 2024 | 2023-11-30 | $34,975 | −$40,582 | −53.71% |
| Q4 2023 | 2023-08-31 | $34,975 | −$58,307 | −62.51% |
| Q3 2023 | 2023-05-31 | $34,975 | −$69,950 | −66.67% |
| Q2 2023 | 2023-02-28 | $34,973 | −$69,952 | −66.67% |
| Q1 2023 | 2022-11-30 | $75,557 | −$350,180 | −82.25% |
| Q4 2022 | 2022-08-31 | $93,282 | $93,282 | — |
| Q3 2022 | 2022-05-31 | $104,925 | $104,925 | — |
| Q2 2022 | 2022-02-28 | $104,925 | $104,925 | — |
| Q1 2022 | 2021-11-30 | $425,737 | $425,737 | — |
| Q4 2021 | 2021-08-31 | $0 | — | — |
| Q3 2021 | 2021-05-31 | $0 | — | — |
| Q2 2021 | 2021-02-28 | $0 | — | — |
| Q1 2021 | 2020-11-30 | $0 | — | — |
CNBX Pharmaceuticals stock-based compensation trends
Over the last five fiscal years, CNBX Pharmaceuticals's stock-based compensation decreased from $72,120 to $0, a change of −$72,120. The latest reported quarter, Q1 2026, shows $0.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review CNBX Pharmaceuticals source filings ↗